BARBA OSCAR (GB)
WO2013005157A1 | 2013-01-10 | |||
WO2010042867A2 | 2010-04-15 | |||
WO2020167976A1 | 2020-08-20 | |||
WO2023079294A1 | 2023-05-11 | |||
WO2020167976A1 | 2020-08-20 | |||
WO2023052783A1 | 2023-04-06 | |||
WO2023079294A1 | 2023-05-11 | |||
WO2023118875A1 | 2023-06-29 |
CN112156095A | 2021-01-01 |
DONG ET AL.: "PKM2 binds directly to and phosphorylates histone H3 leading to expression of c-Myc and Cyclin D1 and the proliferation of cancer cells", ACTIVATION OF PKM2 TETRAMER BY SMALL MOLECULES COULD BE AN ATTRACTIVE THERAPY IN CANCER TO CONTAIN TUMOUR GROWTH BY PREVENTING THE NON-METABOLIC FUNCTIONS OF DIMERIC PKM2, 2016
PALSSON-MCDERMOTT ET AL.: "The non-metabolic roles of dimeric PKM2 have been shown to regulate immune responses: PKM2 acts as a transcriptional coactivator of Hif-1a, b-catenin and STAT3 leading to expression of pro-inflammatory cytokines such as IL-1β and TNF", ACTIVATION OF PKM2 BY SMALL MOLECULES TO PREVENT NUCLEAR TRANSLOCATION COULD HAVE THERAPEUTIC BENEFIT IN A RANGE OF INFLAMMATORY AND AUTO-IMMUNE CONDITIONS, SUCH AS RHEUMATOID ARTHRITIS, INFLAMMATORY BOWEL DISEASES, INFLAMMATORY SKIN PATHOLOGIES, COR, 2020
PUCKETT ET AL.: "Work on the impact of altered PKM2 phosphorylation status and resulting decreased catalytic activity", HAS IDENTIFIED PKM2 AS A POTENTIAL CONTRIBUTOR TO INSULIN RESISTANCE IN THE ADIPOSE TISSUE AND MADE AN ASSOCIATION WITH METABOLIC STATUS IN HUMANS, 2021
BETTAIEB ET AL., RESTORING PKM2 ACTIVITY WITH A SMALL MOLECULE ALLOSTERIC ACTIVATOR HAS BEEN SHOWN TO IMPROVE INSULIN SENSITIVITY, 2013
CANGADO ET AL.: "PK-deficient erythrocytes are prematurely removed from the circulation by the spleen through accelerated hemolysis leading to iron accumulation", INCREASE AND/OR RESTORATION OF PKR ACTIVITY TO QUASI-BASAL LEVELS IS THOUGHT TO HAVE POTENTIAL TO TREAT THE PK DEFICIENCY-RELATED COMPLICATIONS, 2018
KUNG ET AL.: "This agent has shown an adequate level of efficacy when dosed in patients presenting PK deficiency by increasing basal haemoglobin levels", HOWEVER, DESPITE THE PROMISING RESULTS, THE HIGH DOSING REGIMEN AND THE BID (TWO TIMES A DAY) DOSING FREQUENCY NEEDED TO ACHIEVE EFFICACY HAVE HIGHLIGHTED THE NEED TO DEVELOP MORE EFFICACIOUS COMPOUNDS WITH A MORE FAVOURABLE PHARMACOKINETIC AND IMPRO, 2017
LEWANDOWSKI ET AL., CELL METAB., vol. 32, no. 5, 2020, pages 736 - 750
ALVES-FILHO ET AL., FRONT IMMUNOL, vol. 7, no. 145, 2016, pages 1 - 7
BARAZZONI ET AL.: "Eating and Weight Disorders - Studies on Anorexia", BULIMIA AND OBESITY, vol. 23, 2018, pages 149 - 157
BETTAIEB ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 288, no. 24, 2013, pages 17360 - 17371
BIANCHI ET AL., HAEMATOLOGICA, vol. 105, no. 9, 2020, pages 2218 - 2228
CANGADO ET AL.: "Hematology", TRANSFUSION AND CELL THERAPY, vol. 40, no. 1, 2018, pages 1 - 2
CHHIPA ET AL., LIFE SCIENCES, 2018, pages 280, Retrieved from the Internet
DONG ET AL., ONCOL LETT., vol. 11, no. 3, 2016, pages 1980 - 1986
GRACE ET AL., N. ENGL. J. MED., vol. 381, no. 10, 2019, pages 933 - 944
KUNG ET AL., CHEMISTRY & BIOLOGY, vol. 19, 2012, pages 1187 - 1198
KUNG ET AL., BLOOD, vol. 130, no. 11, 2017, pages 1347 - 1356
LIU ET AL., J. DIABETES INVESTIG, vol. 12, no. 5, 2020, pages 697 - 709
PALSSON-MCDERMOTT ET AL., CELL RESEARCH, vol. 30, 2020, pages 300 - 314
PUCKETT ET AL., INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 22, 2021, pages 1171
QI ET AL., NAT MED., vol. 23, no. 6, 2017, pages 753 - 762
YI ET AL., FRONT. IMMUNOL, 2021, Retrieved from the Internet
CLAIMS 1. A compound of formula (Ia): wherein: (a) RA is pyrazolyl and RB is pyridinyl substituted by one OMe group to give 6-((1H-pyrazol- 4-yl)sulfonyl)-2-((5-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one ; (b) RA is pyrazolyl substituted by CHF2 and RB is pyrazolyl to give 2-((1H-pyrazol-3- yl)methyl)-6-((1-(difluoromethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one ; (c) RA is pyrazolyl substituted by CH B 2CH2OH and R is dihydrofuro[3,2-b]pyridinyl to give 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-4- yl)sulfonyl)phthalazin-1(2H)-one ; (d) RA is pyrazolyl and RB is 2,3-dihydropyrazolo[5,1-b]oxazolyl to give 6-((1H-pyrazol-4- yl)sulfonyl)-2-((2,3-dihydropyraz l [51b] x z l6 l)m th l) hthalazin-1(2H)-one ; (e) R is pyrazolyl substituted by methyl and R is 2,3-dihydropyrazolo[5,1-b]oxazolyl to give 2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-((1-methyl-1H-pyrazol-4- yl)sulfonyl)phthalazin-1(2H)-one r (f) RA is pyrazolyl and R is pyrazolyl substituted by one Cl and one methyl to give 6- ((1H-pyrazol-3-yl)sulfonyl)-2-((4-chloro-5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one ; or a salt and/or solvate thereof. 2. The compound of formula (Ia) or a salt and/or solvate thereof according to claim 1 which is 6-((1H-pyrazol-4-yl)sulfonyl)-2-((5-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one ; or a salt and/or solvate thereof. 3. The compound of formula (Ia) or a salt and/or solvate thereof according to claim 2 which is 6-((1H-pyrazol-4-yl)sulfonyl)-2-((5-methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one . 4. The compound of formula (Ia) or a salt and/or solvate thereof according to claim 2 which is a salt, such as a pharmaceutically acceptable salt, of 6-((1H-pyrazol-4-yl)sulfonyl)-2-((5- methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one . 5. The compound of formula (Ia) or a salt and/or solvate thereof according to claim 1 which is 2-((1H-pyrazol-3-yl)methyl)-6-((1-(difluoromethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)- one ; or a salt and/or solvate thereof. 6. The compound of formula (Ia) or a salt and/or solvate thereof according to claim 5 which is 2-((1H-pyrazol-3-yl)methyl)-6-((1-(difluoromethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)- one . 7. The compound of formula (Ia) or a salt and/or solvate thereof according to claim 5 which is a salt, such as a pharmaceutically acceptable salt, of 2-((1H-pyrazol-3-yl)methyl)-6-((1- (difluoromethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one . 8. The compound of formula (Ia) or a salt and/or solvate thereof according to claim 1 which is 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-4- yl)sulfonyl)phthalazin-1(2H)-one ; or a salt and/or solvate thereof. 9. The compound of formula (Ia) or a salt and/or solvate thereof according to claim 8 which is 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-4- yl)sulfonyl)phthalazin-1(2H)-one . 10. The compound of formula (Ia) or a salt and/or solvate thereof according to claim 8 which is a salt, such as a pharmaceutically acceptable salt, of 2-((2,3-dihydrofuro[3,2-b]pyridin-5- yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one . 11. The compound of formula (Ia) or a salt and/or solvate thereof according to claim 1 which is 6-((1H-pyrazol-4-yl)sulfonyl)-2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)phthalazin- 1(2H)-one ; or a salt and/or solvate thereof. 12. The compound of formula (Ia) or a salt and/or solvate thereof according to claim 11 which is 6-((1H-pyrazol-4-yl)sulfonyl)-2-((2,3-dihydropyrazolo[5,1-b]oxazol-6- yl)methyl)phthalazin-1(2H)-one . 13. The compound of formula (Ia) or a salt and/or solvate thereof according to claim 11 which is a salt, such as a pharmaceutically acceptable salt, of 6-((1H-pyrazol-4-yl)sulfonyl)-2- ((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)phthalazin-1(2H)-one . 14. The compound of formula (Ia) or a salt and/or solvate thereof according to claim 1 which is 2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-((1-methyl-1H-pyrazol-4- yl)sulfonyl)phthalazin-1(2H)-one ; or a salt and/or solvate thereof. 15. The compound of formula (Ia) or a salt and/or solvate thereof according to claim 14 which is 2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-((1-methyl-1H-pyrazol-4- yl)sulfonyl)phthalazin-1(2H)-one . 16. The compound of formula (Ia) or a salt and/or solvate thereof according to claim 14 which is a salt, such as a pharmaceutically acceptable salt, of 2-((2,3-dihydropyrazolo[5,1- b]oxazol-6-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one . 17. The compound of formula (Ia) or a salt and/or solvate thereof according to claim 1 which is 6-((1H-pyrazol-3-yl)sulfonyl)-2-((4-chloro-5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)- one ; or a salt and/or solvate thereof. 18. The compound of formula (Ia) or a salt and/or solvate thereof according to claim 17 which is 6-((1H-pyrazol-3-yl)sulfonyl)-2-((4-chloro-5-methyl-1H-pyrazol-3-yl)methyl)phthalazin- 1(2H)-one . 19. The compound of formula (Ia) or a salt and/or solvate thereof according to claim 17 which is a salt, such as a pharmaceutically acceptable salt, of 6-((1H-pyrazol-3-yl)sulfonyl)-2- ((4-chloro-5-methyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one . 20. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 19, and one or more pharmaceutically acceptable diluents or carriers. 21. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 19 or a pharmaceutical composition according to claim 20, for use as a medicament. 22. The compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 19, or a pharmaceutical composition according to claim 20, for use in treating or preventing a disease, disorder or condition associated with the function of PK, in particular PKM2 and/or PKLR. 23. Use of a compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 19 or a pharmaceutical composition according to claim 20, in the manufacture of a medicament for treating or preventing a disease, disorder or condition associated with the function of PK, in particular PKM2 and/or PKLR. 24. A method of treating or preventing a disease, disorder or condition associated with the function of PK, in particular PKM2 and/or PKLR, which comprises administering a compound or a pharmaceutically acceptable salt and/or solvate thereof according to any one of claims 1 to 19 or a pharmaceutical composition according to claim 20. 25. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to any one of claims 22 to 24, for treating or preventing an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder. 26. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 25, for treating an inflammatory disease or a disease associated with an undesirable immune response. 27. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 25, for preventing an inflammatory disease or a disease associated with an undesirable immune response. 28. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 25, for treating or preventing an inflammatory disease. 29. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 25, for treating or preventing a disease associated with an undesirable immune response. 30. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 25 wherein the inflammatory disease or disease associated with an undesirable immune response is selected from the group consisting of Crohn’s disease, ulcerative colitis, Type 2 diabetes, atopic dermatitis, hidradenitis suppurativa, psoriasis, bullous pemphigoid, pemphigus vulgaris, limited and diffuse scleroderma, Sjogren’s syndrome, polymyositis, dermatomyositis, Behcet’s disease, wound healing, rheumatoid arthritis, systemic lupus erythematosus, cutaneous lupus erythematosus, graft-vs-host disease, multiple sclerosis, organ fibrosis (including liver, lung, kidney), COPD and asthma. 31. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 25, wherein the inflammatory disease or disease associated with an undesirable immune response is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, multiple sclerosis, psoriasis, inflammatory bowel disease (including ulcerative colitis and Crohn’s disease), atopic dermatitis, fibrosis, uveitis, cryopyrin- associated periodic syndromes, Muckle-Wells syndrome, juvenile idiopathic arthritis, chronic obstructive pulmonary disease and asthma. 32. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 31, wherein the inflammatory disease or disease associated with an undesirable immune response is multiple sclerosis. 33. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 31, wherein the inflammatory disease or disease associated with an undesirable immune response is psoriasis. 34. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 31, wherein the inflammatory disease or disease associated with an undesirable immune response is asthma. 35. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 31, wherein the inflammatory disease or disease associated with an undesirable immune response is chronic obstructive pulmonary disease. 36. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 31, wherein the inflammatory disease or disease associated with an undesirable immune response is systemic lupus erythematosus. 37. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 31, wherein the inflammatory disease or disease associated with an undesirable immune response is rheumatoid arthritis. 38. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 31, wherein the inflammatory disease or disease associated with an undesirable immune response is inflammatory bowel disease (including ulcerative colitis and Crohn’s disease). 39. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 31, wherein the inflammatory disease or disease associated with an undesirable immune response is atopic dermatitis. 40. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 31, wherein the inflammatory disease or disease associated with an undesirable immune response is fibrosis. 41. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 25, for treating cancer. 42. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 25, for preventing cancer. 43. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 41 or 42, wherein cancer is selected from the group consisting of acute lymphoblastic leukaemia, adult; acute lymphoblastic leukaemia, childhood; acute myeloid leukaemia, adult; adrenocortical carcinoma; adrenocortical carcinoma, childhood; aids-related lymphoma; aids-related malignancies; anal cancer; astrocytoma, childhood cerebellar; astrocytoma, childhood cerebral; Barrett’s esophagus (pre- malignant syndrome); bile duct cancer, extrahepatic; bladder cancer; bladder cancer, childhood; bone cancer, osteosarcoma/malignant fibrous histiocytoma; brain stem glioma, childhood; brain tumour, adult; brain tumour, brain stem glioma, childhood; brain tumour, cerebellar astrocytoma, childhood; brain tumour, cerebral astrocytoma/malignant glioma, childhood; brain tumour, ependymoma, childhood; brain tumour, medulloblastoma, childhood; brain tumour, supratentorial primitive neuroectodermal tumours, childhood; brain tumour, visual pathway and hypothalamic glioma, childhood; brain tumour, childhood (other); breast cancer; breast cancer and pregnancy; breast cancer, childhood; breast cancer, male; bronchial adenomas/carcinoids, childhood; carcinoid tumour, childhood; carcinoid tumour, gastrointestinal; carcinoma, adrenocortical; carcinoma, islet cell; carcinoma of unknown primary; central nervous system lymphoma, primary; cerebellar astrocytoma, childhood; cerebral astrocytoma/malignant glioma, childhood; cervical cancer; childhood cancers; chronic lymphocytic leukaemia; chronic myelogenous leukaemia; chronic myeloproliferative disorders; clear cell sarcoma of tendon sheaths; colon cancer; colorectal cancer; colorectal cancer, childhood; cutaneous t-cell lymphoma; endometrial cancer; ependymoma, childhood; epithelial cancer, ovarian; oesophageal cancer; oesophageal cancer, childhood; Ewing’s family of tumours; extracranial germ cell tumour, childhood; extragonadal germ cell tumour; extrahepatic bile duct cancer; eye cancer, intraocular melanoma; eye cancer, retinoblastoma; gallbladder cancer; gastric (stomach) cancer; gastric (stomach) cancer, childhood; gastrointestinal carcinoid tumour; germ cell tumour, extracranial, childhood; germ cell tumour, extragonadal; germ cell tumour, ovarian; gestational trophoblastic tumour; glioma, childhood brain stem; glioma, childhood visual pathway and hypothalamic; hairy cell leukaemia; head and neck cancer; hepatocellular (liver) cancer; hepatocellular (liver) cancer, adult (primary); hepatocellular (liver) cancer, childhood (primary); cancer of the esophagus; Hodgkin’s lymphoma; Hodgkin’s lymphoma, adult; Hodgkin’s lymphoma, childhood; Hodgkin’s lymphoma during pregnancy; hypopharyngeal cancer; hypothalamic and visual pathway glioma, childhood; intraocular melanoma; islet cell carcinoma (endocrine pancreas); cancer of the endocrine system (e.g., cancer of the thyroid, pancreas, parathyroid or adrenal glands); Kaposi’s sarcoma; kidney cancer; laryngeal cancer; laryngeal cancer, childhood; leukaemia, acute lymphoblastic, adult; leukaemia, acute lymphoblastic, childhood; leukaemia, acute myeloid, adult; leukaemia, acute myeloid, childhood; leukaemia, chronic lymphocytic; leukaemia, chronic myelogenous; leukaemia, hairy cell; lymphocytic lymphoma; lip and oral cavity cancer; liver cancer, adult (primary); liver cancer, childhood (primary); lung cancer; lung cancer, non-small cell; lung cancer, small cell; lymphoblastic leukaemia, adult acute; lymphoblastic leukaemia, childhood acute; lymphocytic leukaemia, chronic; lymphoma, aids- related; lymphoma, central nervous system (primary); lymphoma, cutaneous t-cell; lymphoma, Hodgkin’s, adult; lymphoma, Hodgkin’s, childhood; lymphoma, Hodgkin’s during pregnancy; lymphoma, non-Hodgkin’s, adult; lymphoma, non-Hodgkin’s, childhood; lymphoma, non-Hodgkin’s during pregnancy; lymphoma, primary central nervous system; macroglobulinemia, Waldenstrom’s; male breast cancer; malignant mesothelioma, adult; malignant mesothelioma, childhood; malignant thymoma; medulloblastoma, childhood; melanoma; melanoma, intraocular; Merkel cell carcinoma; mesothelioma, malignant; metastatic squamous neck cancer with occult primary; multiple endocrine neoplasia syndrome, childhood; multiple myeloma/plasma cell neoplasm; mycosis fungoides; myelodysplastic syndromes; myelogenous leukaemia, chronic; myeloid leukaemia, childhood acute; myeloma, multiple; myeloproliferative disorders, chronic; nasal cavity and paranasal sinus cancer; nasopharyngeal cancer; nasopharyngeal cancer, childhood; neoplastic cutaneous disease; neuroblastoma; non-Hodgkin’s lymphoma, adult; non-Hodgkin’s lymphoma, childhood; non- Hodgkin’s lymphoma during pregnancy; non-small cell lung cancer; neoplasms of the central nervous system (e.g., primary CNS lymphoma, spinal axis tumors, medulloblastoma, brain stem gliomas or pituitary adenomas); oat-cell cancer; oral cancer, childhood; oral cavity and lip cancer; oropharyngeal cancer; osteosarcoma/malignant fibrous histiocytoma of bone; ovarian cancer; ovarian cancer, childhood; ovarian epithelial cancer; ovarian germ cell tumour; ovarian low malignant potential tumour; pediatric malignancy; pancreatic cancer; pancreatic cancer, childhood; pancreatic cancer, islet cell; paranasal sinus and nasal cavity cancer; parathyroid cancer; penile cancer; pheochromocytoma; pineal and supratentorial primitive neuroectodermal tumours, childhood; pituitary tumour; plasma cell neoplasm/multiple myeloma; pleuropulmonary blastoma; pregnancy and breast cancer; pregnancy and Hodgkin’s lymphoma; pregnancy and non-Hodgkin’s lymphoma; primary central nervous system lymphoma; primary liver cancer, adult; primary liver cancer, childhood; prostate cancer (particularly hormone-refractory); chronic or acute leukemia; solid tumors of childhood; hypereosinophilia; rectal cancer; renal cell (kidney) cancer; renal cell cancer, childhood; renal pelvis and ureter, transitional cell cancer; retinoblastoma; rhabdomyosarcoma, childhood; salivary gland cancer; salivary gland cancer, childhood; sarcoma, Ewing’s family of tumours; sarcoma, Kaposi’s; sarcoma (osteosarcoma)/malignant fibrous histiocytoma of bone; sarcoma, rhabdomyosarcoma, childhood; sarcomas of soft tissues; sarcoma, soft tissue, adult; sarcoma, soft tissue, childhood; Sezary syndrome; skin cancer; skin cancer, childhood; skin cancer (melanoma); skin carcinoma, Merkel cell; small cell lung cancer; dermatofibrosarcoma protuberans; small intestine cancer; soft tissue sarcoma, adult; soft tissue sarcoma, childhood; cancer of the head and neck; squamous neck cancer with occult primary, metastatic; stomach (gastric) cancer; stomach (gastric) cancer, childhood; supratentorial primitive neuroectodermal tumours, childhood; t-cell lymphoma, cutaneous; testicular cancer; thymoma, childhood; thymoma, malignant; thyroid cancer; thyroid cancer, childhood; transitional cell cancer of the renal pelvis and ureter; trophoblastic tumour, gestational; unknown primary site, cancer of, childhood; unusual cancers of childhood; ureter and renal pelvis, transitional cell cancer; urethral cancer; cancer of the ureter (e.g., renal cell carcinoma, carcinoma of the renal pelvis); cancer of the penis; gynecologic tumors; uterine cancer; uterine sarcoma; carcinoma of the fallopian tubes; carcinoma of the endometrium; vaginal cancer; carcinoma of the vagina; carcinoma of the vulva; visual pathway and hypothalamic glioma, childhood; vulvar cancer; Waldenstrom’s macro globulinemia; and Wilms’ tumour. 44. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 43, wherein cancer is selected from the group consisting of lung cancer; NSCLC (non-small cell lung cancer); oat-cell cancer; bone cancer; pancreatic cancer; skin cancer; dermatofibrosarcoma protuberans; cancer of the head and neck; cutaneous or intraocular melanoma; uterine cancer; ovarian cancer; colo- rectal cancer; anal cancer; stomach cancer; colon cancer; breast cancer; gynecologic tumors (e.g., uterine sarcomas, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina or carcinoma of the vulva); Hodgkin’s Disease; hepatocellular cancer; cancer of the esophagus; small intestine cancer; cancer of the endocrine system (e.g., cancer of the thyroid, pancreas, parathyroid or adrenal glands); sarcomas of soft tissues; urethral cancer; cancer of the penis; prostate cancer (particularly hormone-refractory); chronic or acute leukemia; solid tumors of childhood; hypereosinophilia; lymphocytic lymphomas; bladder cancer; kidney cancer; cancer of the ureter (e.g., renal cell carcinoma, carcinoma of the renal pelvis); pediatric malignancy; neoplasms of the central nervous system (e.g., primary CNS lymphoma, spinal axis tumors, medulloblastoma, brain stem gliomas or pituitary adenomas); Barrett’s esophagus (pre-malignant syndrome) and neoplastic cutaneous disease. 45. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 25, for treating obesity. 46. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 25, for preventing obesity. 47. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 25, for treating a diabetic disease. 48. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 25, for preventing a diabetic disease. 49. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 47 or 48, wherein the diabetic disease is selected from diabetes mellitus and a diabetic complication. 50. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 49, wherein diabetes mellitus is Type 1 diabetes. 51. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 49, wherein diabetes mellitus is Type 2 diabetes. 52. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 49, wherein the diabetic complication is selected from the group consisting of coronary artery disease, peripheral artery disease, stroke, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic kidney disease and NASH. 53. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 25, for treating a blood disorder. 54. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 25, for preventing a blood disorder. 55. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 53 or 54, wherein the blood disorder is selected from the group consisting of thalassemia (e.g. beta-thalassemia), hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia (or Bassen-Kornzweig syndrome), paroxysmal nocturnal hemoglobinuria, acquired hemolytic anaemia (e.g., congenital anaemias (e.g., enzymopathies)), anaemia of chronic diseases, pyruvate kinase deficiency (PKD) and sickle cell disease. 56. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to any one of claims 21 to 55, wherein the compound is for administration to a human subject. 57. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to any one of claims 21 to 56, for use in combination with a further therapeutic agent. 58. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to any one of claims 26 to 40, for use in combination with a further therapeutic agent selected from the group consisting of a corticosteroid (glucocorticoid), retinoid (e.g. acitretin, isotretinoin, tazarotene), anthralin, vitamin D analogue (e.g. cacitriol, calcipotriol), calcineurin inhibitors (e.g. tacrolimus, pimecrolimus), phototherapy or photochemotherapy (e.g. psoralen ultraviolet irradiation, PUVA) or other form of ultraviolet light irradiation therapy, ciclosporine, a thiopurine (e.g. azathioprine, 6- mercaptopurine), methotrexate, an anti-TNFα agent (e.g. infliximab, etanercept, adalimumab, certolizumab, golimumab or a biosimilar), phosphodiesterase-4 (PDE4) inhibitors (e.g. apremilast, crisaborole), anti-IL-17 agent (e.g. brodalumab, ixekizumab, secukinumab), anti-IL12/IL-23 agent (e.g. ustekinumab, briakinumab), anti-IL-23 agent (e.g. guselkumab, tildrakizumab), JAK (Janus Kinase) inhibitor (e.g. tofacitinib, ruxolitinib, baricitinib, filgotinib, upadacitinib), plasma exchange, intravenous immune globulin (IVIG), cyclophosphamide, anti-CD20 B cell depleting agent (e.g. rituximab, ocrelizumab, ofatumumab, obinutuzumab), anthracycline analogue (e.g. mitoxantrone), cladribine, sphingosine 1-phosphate receptor modulator or sphingosine analogue (e.g. fingolimod, siponimod, ozanimod, etrasimod), interferon beta preparation (including interferon beta 1b/1a), glatiramer, anti-CD3 therapy (e.g. OKT3), anti-CD52 targeting agent (e.g. alemtuzumab), leflunomide, teriflunomide, gold compound, laquinimod, potassium channel blocker (e.g. dalfampridine/4-aminopyridine), mycophenolic acid, mycophenolate mofetil, purine analogue (e.g. pentostatin), mTOR (mechanistic target of rapamycin) pathway inhibitor (e.g. sirolimus, everolimus), anti-thymocyte globulin (ATG), IL-2 receptor (CD25) inhibitor (e.g. basiliximab, daclizumab), anti-IL-6 receptor or anti-IL-6 agent (e.g. tocilizumab, siltuximab), Bruton’s tyrosine kinase (BTK) inhibitor (e.g. ibrutinib), tyrosine kinase inhibitor (e.g. imatinib), ursodeoxycholic acid, hydroxychloroquine, chloroquine, B cell activating factor (BAFF, also known as BlyS, B lymphocyte stimulator) inhibitor (e.g. belimumab, blisibimod), other B cell targeted therapy including a fusion protein targeting both APRIL (A Proliferation-Inducing Ligand) and BlyS (e.g. atacicept), PI3K inhibitor including pan-inhibitor or one targeting the p110δ and/or p110γ containing isoforms (e.g. idelalisib, copanlisib, duvelisib), an interferon α receptor inhibitor (e.g. anifrolumab, sifalimumab), T cell co-stimulation blocker (e.g. abatacept, belatacept), thalidomide and its derivatives (e.g. lenalidomide), dapsone, clofazimine, a leukotriene antagonist (e.g. montelukast), theophylline, anti-IgE therapy (e.g. omalizumab), an anti-IL-5 agent (e.g. mepolizumab, reslizumab), a long-acting muscarinic agent (e.g. tiotropium, aclidinium, umeclidinium), a PDE4 inhibitor (e.g. roflumilast), riluzole, a free radical scavenger (e.g. edaravone), a proteasome inhibitor (e.g. bortezomib), a complement cascade inhibitor including one directed against C5 (e.g. eculizumab), immunoadsor, antithymocyte globulin, 5- aminosalicylates and their derivatives (e.g. sulfasalazine, balsalazide, mesalamine), an anti- integrin agent including one targeting α4β1 and/or α4β7 integrins (e.g. natalizumab, vedolizumab), an anti-CD11-α agent (e.g. efalizumab), a non-steroidal anti-inflammatory drug (NSAID) including a salicylate (e.g. aspirin), a propionic acid (e.g. ibuprofen, naproxen), an acetic acid (e.g. indomethacin, diclofenac, etodolac), an oxicam (e.g. meloxicam) a fenamate (e.g. mefenamic acid), a selective or relatively selective COX-2 inhibitor (e.g. celecoxib, etroxicoxib, valdecoxib and etodolac, meloxicam, nabumetone), colchicine, an IL-4 receptor inhibitor (e.g. dupilumab), topical/contact immunotherapy (e.g. diphenylcyclopropenone, squaric acid dibutyl ester), anti-IL-1 receptor therapy (e.g. anakinra), IL-1β inhibitor (e.g. canakinumab), IL-1 neutralising therapy (e.g. rilonacept), chlorambucil, a specific antibiotic with immunomodulatory properties and/or ability to modulate NRF2 (e.g. tetracyclines including minocycline, clindamycin, macrolide antibiotics), anti-androgenic therapy (e.g. cyproterone, spironolactone, finasteride), pentoxifylline, ursodeoxycholic acid, obeticholic acid, fibrate, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, a VEGF (vascular endothelial growth factor) inhibitor (e.g. bevacizumab, ranibizumab, pegaptanib, aflibercept), pirfenidone or mizoribine. 59. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to any one of claims 41 to 44, for use in combination with a further therapeutic agent selected from the group consisting of a palliative treatment such as selected from the group consisting of: antiemetic agents, medication intended to alleviate pain such as opioids, medication used to decrease high blood uric acid levels such as allopurinol or rasburicase, anti-depressants, sedatives, anti-convulsant drugs, laxatives, anti-diarrhoeal drugs and/or antacids. 60. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to any one of claims 41 to 44, for use in combination with an additional cancer treatment selected from the group consisting of chemotherapy, a targeted therapy, immunotherapy and an hormonal therapy. 61. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 60, wherein the chemotherapy agent is selected from the group consisting of Aclarubicin, Actinomycin, Alitretinon, Altretamine, Aminopterin, Aminolevulinic acid, Amrubicin, Amsacrine, Anagrelide, Arsenic trioxide, Asparaginase, Atrasentan, Belotecan, Bexarotene, endamustine, Bleomycin, Bortezomib, Busulfan, Camptothecin, Capecitabine, Carboplatin, Carboquone, Carmofur, Carmustine, Celecoxib, Chlorambucil, Chlormethine, Cisplatin, Cladribine, Clofarabine, Crisantaspase, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin, Decitabine, Demecolcine, Docetaxel, Doxorubicin, Efaproxiral, Elesclomol, Elsamitrucin, Enocitabine, Epirubicin, Estramustine, Etoglucid, Etoposide, Floxuridine, Fludarabine, Fluorouracil (5FU), Fotemustine, Gemcitabine, Gliadel implants, Hydroxycarbamide, Hydroxyurea, Idarubicin, Ifosfamide, Irinotecan, Irofulven, Ixabepilone, Larotaxel, Leucovorin, Liposomal doxorubicin, Liposomal daunorubicin, Lonidamine, Lomustine, Lucanthone, Mannosulfan, Masoprocol, Melphalan, Mercaptopurine, Mesna, Methotrexate, Methyl aminolevulinate, Mitobronitol, Mitoguazone, Mitotane, Mitomycin, Mitoxantrone, Nedaplatin, Nimustine, Oblimersen, Omacetaxine, Ortataxel, Oxaliplatin, Paclitaxel, Pegaspargase, Pemetrexed, Pentostatin, Pirarubicin, Pixantrone, Plicamycin, Porfimer sodium, Prednimustine, Procarbazine, Raltitrexed, Ranimustine, Rubitecan, Sapacitabine, Semustine, Sitimagene ceradenovec, Satraplatin, Streptozocin, Talaporfin, Tegafur- uracil, Temoporfin, Temozolomide, Teniposide, Tesetaxel, Testolactone, Tetranitrate, Thiotepa, Tiazofurin, Tioguanine, Tipifarnib, Topotecan, Trabectedin, Triaziquone, Triethylenemelamine, Triplatin, Tretinoin, Treosulfan, Trofosfamide, Uramustine, Valrubicin, Verteporfin, Vinblastine, Vincristine, Vindesine, Vinfhmine, Vinorelbine, Vorinostat, and Zorubicin. 62. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 60, wherein the targeted therapy is selected from the group consisting of Axitinib, Bosutinib, Cediranib, dasatinib, erlotinib, imatinib, gefitinib, lapatinib, Lestaurtinib, Nilotinib, Semaxanib, Sorafenib, Sunitinib, Vandetanib, Alvocidib, Seliciclib, Herceptin, rituximab, Tositumomab, Cetuximab, Panitumumab, Trastuzumab, Alemtuzumab, Bevacizumab, Edrecolomab, Gemtuzumab, Aflibercept, Denileukin diftitox and Bexxar. 63. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to claim 45 or claim 46, for use in combination with a gastric or pancreatic lipase inhibitor (such as orlistat); a lipid lowering agent (such as a statin, a fibrate, niacin or a derivative thereof (such as acipimox), lecithin, a bile acid sequesterant, ezetimibe, lomitapide, a phytosterol, an omega-3 supplement, a PCSK9 inhibitor); a CB-1 antagonist; a lipoxygenase inhibitor; a somostatin analogue; an insulin compound or insulin analogue (such as human insulin, insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin degludec); an insulin sensitising agent such as a PPAR-gamma agonist, PPAR- alpha agonist or mixed PPAR-gamma/alpha agonist (such as metformin, pioglitazone or rosiglitazone); an insulin secretagogue (such as a nateglinide or repaglinide, or a sulfonylurea such as gliclazide, glimeperide, limepiride, glyburide); an SGLT2 inhibitor (such as dapagliflozin, canagliflozin or empagliflozin); an amylin analogue (such as pramlintide); a DPPIV inhibitor (such as sitagliptin, saxagliptin, linagliptin, alogliptin or vildagliptin); a GLP-1 agonist (such as albiglutide, dulaglutide, exenatide, liraglutide, semaglutide or lixisenatide); an alpha-glucosidase inhibitor (such as acarbose, miglitol or voglibose); a phosphodiesterase inhibitor (such as pentoxifylline); a glycogen phosphorylase inhibitor; an MCH-1 antagonist; a glucokinase activator; a glucagon antagonist; an insulin signalling agonist; a PTP1B inhibitor; a gluconeogenesis inhibitor; a GSK inhibitor or a galanin receptor agonist. 64. The compound or a pharmaceutically acceptable salt and/or solvate thereof for use, pharmaceutical composition for use, use or method according to any one of claims 47 to 52, for use in combination with a gastric or pancreatic lipase inhibitor (such as orlistat); a lipid lowering agent (such as a statin, a fibrate, niacin or a derivative thereof (such as acipimox), lecithin, a bile acid sequesterant, ezetimibe, lomitapide, a phytosterol, an omega-3 supplement, a PCSK9 inhibitor); a CB-1 antagonist; a lipoxygenase inhibitor; a somostatin analogue; an insulin compound or insulin analogue (such as human insulin, insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin degludec); an insulin sensitising agent such as a PPAR-gamma agonist, PPAR-alpha agonist or mixed PPAR-gamma/alpha agonist (such as metformin, pioglitazone or rosiglitazone); an insulin secretagogue (such as a nateglinide or repaglinide, or a sulfonylurea such as gliclazide, glimeperide, limepiride, glyburide); an SGLT2 inhibitor (such as dapagliflozin, canagliflozin or empagliflozin); an amylin analogue (such as pramlintide); a DPPIV inhibitor (such as sitagliptin, saxagliptin, linagliptin, alogliptin or vildagliptin); a GLP-1 agonist (such as albiglutide, dulaglutide, exenatide, liraglutide, semaglutide or lixisenatide); an alpha- glucosidase inhibitor (such as acarbose, miglitol or voglibose); a phosphodiesterase inhibitor (such as pentoxifylline); a glycogen phosphorylase inhibitor; an MCH-1 antagonist; a glucokinase activator; a glucagon antagonist; an insulin signalling agonist; a PTP1B inhibitor; a gluconeogenesis inhibitor; a GSK inhibitor or a galanin receptor agonist. 65. A compound selected from the group consisting of: 2-((5-methoxypyridin-2-yl)methyl)-6-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4- yl)thio)phthalazin-1(2H)-one; 6-((1-(difluoromethyl)-1H-pyrazol-4-yl)thio)-2-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3- yl)methyl)phthalazin-1(2H)-one; 6-((1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-pyrazol-4-yl)thio)-2-((2,3-dihydrofuro[3,2-b]pyridin- 5-yl)methyl)phthalazin-1(2H)-one; 2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4- yl)thio)phthalazin-1(2H)-one; 2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-((1-methyl-1H-pyrazol-4-yl)thio)phthalazin- 1(2H)-one; and 2-((4-chloro-5-methyl-1H-pyrazol-3-yl)methyl)-6-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3- yl)sulfonyl)phthalazin-1(2H)-one; or a salt thereof. 66. A process for preparing a compound of formula (Ia) as described in any one of claims 1 to 19, or a salt, such as a pharmaceutically acceptable salt and/or solvate thereof, which comprises oxidising a compound of formula (IIa): ) or a salt and/or solvate thereof; using an oxidising agent such as Oxone; wherein RA and RB are defined in any one of claims 1 to 19. |
Step 1 To a solution of 4-iodo-1H-pyrazole (80 g, 412 mmol) and 3,4-dihydro-2H-pyran (54 g, 618 mmol) in MeCN (1.2 L) was added TsOH (708 mg, 4.2 mmol) at RT. The reaction mixture was stirred at 85 °C for 16 h. After LCMS indicated the reaction was complete, The mixture was concentrated at 45 °C under reduced pressure. The residue was purified by flash column chromatography to give 4-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (100 g) as a white solid. MS (ES + ): 279.2 (M+H) + Step 2 To a solution of 4-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (100 g, 360 mmol), 2-ethylhexyl 3-mercaptopropanoate (94 g, 432 mmol), Pd 2 dba 3 (13 g, 14.4 mmol) and Xantphos (16.6 g, 28.8 mmol) in DMF (1 L) was added DIPEA (140 g, 1080 mmol) at RT. The reaction mixture was stirred at 100 °C for 16 h. After LCMS indicated the reaction was complete, the mixture was extracted with EtOAc (600 mL × 3) and concentrated at 45 °C under reduced pressure. The residue was purified by flash column chromatography to give 2-ethylhexyl 3-((1-(tetrahydro-2H-pyran-2-yl)- 1H-pyrazol-4-yl)thio)propanoate (116 g) as a yellow oil. MS (ES + ): 369.3 (M+H) + Step 3 A mixture of 2-ethylhexyl 3-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)thio)propan oate (116 g, 315 mmol) in THF (2 L) was added NaOEt (252 mL, 630 mmol, 2.5 M of solution EtOH) at 0 °C. The reaction was stirred at 0 °C for 0.5 h. After LCMS indicated the reaction was complete, the reaction mixture was quenched with HCl (1M) until pH to 6. The mixture was extracted with EtOAc (600 mL × 3). The organic layers were concentrated at 40 °C under reduced pressure and purified by flash column chromatography to give 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-thiol (45 g) as an oil, which was used in the next step without further purification. MS (ES + ): 101.4 (M+H) + Intermediate 4: 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-3-thiol Step 1 To a solution of 3-iodo-1H-pyrazole (5.0 g, 25.8 mmol) and 3,4-dihydro-2H-pyran (3.3 g, 38.7 mmol) in MeCN (50 mL) was added p-TsOH (43 mg, 0.3 mmol) at room temperature, and the reaction mixture was stirred at 80 °C for 16 hours. After LCMS indicated the reaction was completed, the reaction mixture was concentrated at 45 °C under reduced pressure. The residue was purified by flash column chromatography (25 g, petroleum ether/ tert-Butyl methyl ether = 100:0~90:10) to give 3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (6.6 g, 100% purity) as a yellow oil. MS (ES + ): 279.1 (M+H)+. Step 2 To a solution of 3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (6.6 g, 23.7 mmol), 2-ethylhexyl 3-mercaptopropanoate (6.7 g, 30.8 mmol), Pd2dba3 (540 mg, 0.59 mmol) and Xantphos (685 mg, 1.19 mmol) in DMF (100 mL) was added DIPEA (9.2 g, 71.1 mmol) at room temperature. The reaction mixture was stirred at 100 °C for 16 hours. After LCMS indicated the reaction was completed, water (50 mL) was added and the mixture was extracted with EtOAc (50 mL×3). The combined organic layer was concentrated at 45 °C under reduced pressure. The residue was purified by flash column chromatography (120 g, petroleum ether/ tert-Butyl methyl ether = 100:00~80:20) to give 2-ethylhexyl 3-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3- yl)thio)propanoate (7.1 g, 44.18% purity) as a yellow oil. MS (ES + ): 369.3 (M+H) + Step 3 A mixture of 2-ethylhexyl 3-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)thio)propan oate (7.1g, 19.3 mmol) in THF (150 mL) was added EtONa (15 mL, 2.5 M of solution EtOH) at 0 °C. The reaction was stirred at 0 °C for 0.5 hours. After LCMS indicated the reaction was completed, the reaction mixture pH was adjusted with careful addition of aq. HCl (1M) until pH = 6. The mixture was extracted with EtOAc (800 mL × 3). The organic layers were concentrated at 40 °C under reduced pressure. The residue was purified by flash column chromatography (40 g, petroleum ether/ tert-Butyl methyl ether = 100:0-60: 40) to give 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole- 3-thiol (2.8 g, 100% purity) as a yellow oil. MS (ES + ): 185.3 (M+H)+. Intermediate 5: (4-chloro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3 -yl)methanol DHP, TsOH Cl O Cl O H Step 1 A mixture of ethyl 5-methyl-1H-pyrazole-3-carboxylate (2.0 g, 12.97 mmol) and NCS (2.42 g, 18.16 mmol) in DMF (30 mL) was stirred at room temperature for 1 hour. After LCMS indicated the reaction was completed, the reaction mixture was reaction mixture was diluted with water (30 mL) and extracted with EtOAc (50 mL×4). The organic layers were washed with sat.aq.NH4Cl (100 mL×2), concentrated and purified by flash column chromatography (40 g, petroleum ether/tert-butyl methyl ether = 100:00~20:80) to give ethyl 4-chloro-5-methyl-1H-pyrazole-3- carboxylate (2.0 g, 68% purity) as a white solid. MS (ES + ): 189.1 (M+H)+. Step 2 A mixture of ethyl 4-chloro-5-methyl-1H-pyrazole-3-carboxylate (2.0 g, 5.30 mmol), 3,4-dihydro- 2H-pyran (892 mg , 10.6 mmol) and 4-methylbenzenesulfonic acid (86 mg, 0.5 mmol) in MeCN (15 mL) was stirred at 70 °C overnight. After LCMS indicated the reaction was completed, the reaction mixture was concentrated to remove MeCN. The crude product was purified by flash column chromatography (20 g, petroleum ether/tert-butyl methyl ether = 100:00~85:15) to give ethyl 4-chloro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-3 -carboxylate (760 mg, 79% purity) as a yellow oil. MS (ES + ): 189.2 (M+H)+. Step 3 To a solution of ethyl 4-chloro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-3 -carboxylate (760 mg, 2.79 mmol) in THF (4 mL) was added LiBH 4 (5.6 mL, 5.60 mmol, 1 M in THF) and the reaction mixture was stirred at room temperature for 4 hours. After LCMS indicated the reaction was completed, the reaction mixture was quenched with sat.aq. NH 4 Cl until the gas evolution subsided. The suspension was extracted with DCM (50 mL × 4). The organic layers were then dried over Na2SO4, filtered and concentrated at 40 °C under reduced pressure to give the title product (540 mg, 86% purity) as a white solid. MS (ES + ): 231.2 (M+H)+. Intermediate 6: 6-mercapto-2-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3- yl)methyl)phthalazin-1(2H)-one St p A suspension of 6-bromophthalazin-1(2H)-one (2.117 g, 98% Wt, 1 Eq, 9.217 mmol) and cesium carbonate (6.006 g, 2.0 Eq, 18.43 mmol) in DMF (40 mL) was stirred at 80 °C for 1 h and then allowed to cool to RT. A solution of 3-(chloromethyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (2.055 g, 9.217 mmol) in DMF (10 mL) was added and the reaction mixture was stirred at RT for 20 h. EtOAc (150 mL) was added and the reaction mixture was washed with water (100 mL). The organic layer was collected and the aqueous was extracted with EtOAc (3 x 100 mL). The combined organic extracts were washed with 50% brine (2 x 100 mL), brine (100 mL) and concentrated in vacuo to afford the crude product. The crude product was purified by chromatography on silica gel to afford 6-bromo-2-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3- yl)methyl)phthalazin-1(2H)-one (Intermediate 6A, 2.192 g) as an off-white solid. MS (ES + ): 389/391 (M+H) + . Step 2 A solution of 6-bromo-2-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)met hyl)phthalazin-1(2H)- one (1.47 g, 3.40 mmol) in DMF (30 mL) was sparged with N2 for 5 minutes. DIPEA (879 mg, 1.18 mL, 2.00 Eq, 6.80 mmol), Xantphos (197 mg, 340 µmol), Pd2(dba)3 (156 mg, 170 µmol) and 2- ethylhexyl 3-mercaptopropanoate (852 mg, 3.90 mmol) were added sequentially and the reaction mixture was stirred at 100 °C for 90 min. 2-ethylhexyl 3-mercaptopropanoate (0.20 mL, 0.876 mmol) was added and stirred at 100 °C for 90 min. The reaction mixture was concentrated in vacuo and the residue was azeotroped with toluene (3 times) to afford the crude product. The crude product was purified by chromatography on silica gel to afford 2-ethylhexyl 3-((1-oxo-2-((1- (tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)methyl)-1,2-dihyd rophthalazin-6-yl)thio)propanoate (1.648 g) as a thick yellow oil. MS (ES + ): 527 (M+H) + . Step 3 A stirred solution of 2-ethylhexyl 3-((1-oxo-2-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3- yl)methyl)-1,2-dihydrophthalazin-6-yl)thio)propanoate (1.64 g, 2.77 mmol) in THF (25 mL) was treated with sodium ethoxide (2.13 g, 6.56 mmol) dropwise. The reaction mixture was stirred at room temperature for 1 h and then diluted with DCM (100 mL) and sat. aq. NH4Cl (100 mL). The organic layer was collected and the aqueous was extracted with DCM (2 x 50 mL). The combined organic extracts were washed with 50% brine (50 mL), dried (phase separator) and concentrated in vacuo to afford the crude product. The crude product was purified by chromatography on silica gel to afford the title compound (715 mg) as a pale pink solid. 1 H NMR (400 MHz, DMSO-d6) δ 8.29 (s, 1H), 8.10 (d, J = 8.4 Hz, 1H), 7.83 – 7.72 (m, 3H), 6.34 (s, 1H), 6.15 (d, J = 2.4 Hz, 1H), 5.31 (dd, J = 10.3, 2.4 Hz, 1H), 5.24 (s, 2H), 3.94 – 3.85 (m, 1H), 3.58 (ddd, J = 11.5, 8.6, 6.3 Hz, 1H), 2.03 (tdd, J = 12.5, 10.0, 3.6 Hz, 1H), 1.95 – 1.81 (m, 2H), 1.70 – 1.57 (m, 1H), 1.50 (tq, J = 8.0, 3.9 Hz, 2H). MS (ES + ): 343 (M+H) + . Intermediate 7: 6-mercaptophthalazin-1(2H)-one A mixture of 6-bromophthalazin-1(2H)-one (0.60 g, 1 Eq, 2.7 mmol), 2-ethylhexyl 3- mercaptopropanoate (0.61 g, 0.64 mL, 1.05 Eq, 2.8 mmol), cesium carbonate (1.7 g, 2 Eq, 5.3 mmol), Xantphos (0.15 g, 0.1 Eq, 0.27 mmol), and Pd2(dba)3 (0.12 g, 0.05 Eq, 0.13 mmol) in DMF (12 mL) was heated to 100 °C for 12 h. After cooling to RT the reaction mixture was diluted with water (50 mL). then extracted with DCM (20 mL). The aqueous layer was acidified with 1 M HCl, then extracted with EtOAc (2 x 50 mL). The organic phase was collected, dried (MgSO4) and evaporated under reduced pressure, giving the title compound (0.33 g) as a sticky orange solid. MS (ES + ): 179 (M+H) + . Intermediate 8: 1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-iodo-1H-pyrazole A mixture of 3-iodopyrazole (300 mg, 1 E q, 1.55 mmol), (2-bromoethoxy)dimethyl-tert-butylsilane (407 mg, 366 µL, 1.1 Eq, 1.70 mmol) and potassium carbonate (321 mg, 1.5 Eq, 2.32 mmol) in MeCN (10.0 mL) was heated at 85 °C for 24 h. The reaction mixture was cooled to RT, diluted with DCM (10 mL) then filtered through celite with further wash with DCM (20 mL) and MeOH (10 mL). The residue (oil and solid) was partitioned between EtOAc (20 mL) and water (10 mL). The organic was washed with brine (10 mL x 2), dried with MgSO4 and concentrated under reduced pressure to afford crude product as a clear yellow liquid (536 mg) containing a mixture of regioisomers. The crude was dissolved in DCM (5 mL), concentrated onto silica and purified by chromatography to afford the title compound (108.5 mg) as a clear colourless oil. 1 H NMR (400 MHz, MeOD) δ 7.51 (d, J = 2.3 Hz, 1H), 6.45 (d, J = 2.3 Hz, 1H), 4.25 (t, J = 5.1 Hz, 2H), 3.96 (t, J = 5.1 Hz, 2H), 0.86 (s, 9H), -0.03 (s, 6H). MS (ES + ): 353 (M+H) + . Intermediate 9: 5-(chloromethyl)-2,3-dihydrofuro[3,2-b]pyridine Step 1 To a solution of methyl furo[3,2-b]pyridine-5-carboxylate (800 mg, 4.52 mmol) was added 10% Pd/C (320 mg, containing 50% water) in MeOH (10 mL), The mixture was stirred at 25 °C for 10 h under H2. After LCMS indicated the reaction is completed, the mixture was dried over Na2SO4, filtered, and concentrated at 30 °C under reduced pressure the residue was purified by flash column chromatography to give methyl 2,3-dihydrofuro[3,2-b]pyridine-5-carboxylate (750 mg) as a yellow solid. MS (ES + ): 180.3 (M+H) + . Step 2 To the solution of methyl 2,3-dihydrofuro[3,2-b]pyridine-5-carboxylate (750 mg, 4.19 mmol) in THF (10 mL) was add Red-Al (2.42 g, 8.38 mmol, 70wt% in toluene) at 0 °C, and the reaction mixture was stirred at RT for 2 h. After LCMS indicated the reaction is completed, the mixture was added NH4Cl (1 mL). The mixture was quenched over Na2SO4, filtered and concentrated at 30 °C under reduced pressure the residue was purified by flash column chromatography to give (2,3- dihydrofuro[3,2-b]pyridin-5-yl)methanol (360 mg) as a yellow solid. MS (ES + ): 152.4 (M+H) + . Step 3 To the solution of (2,3-dihydrofuro[3,2-b]pyridin-5-yl)methanol (140 mg, 0.93 mmol) in DCM (5 mL) was added drop-wise SOCl2 (221 mg, 1.86 mmol) at 0 °C, and the reaction mixture was stirred at RT for 2 h. After LCMS indicated the reaction was complete, the mixture was concentrated at 30 °C under reduced pressure to remove DCM and SOCl2 to give 5- (chloromethyl)-2,3-dihydrofuro[3,2-b]pyridine (150 mg) as a yellow oil, which was used to the next step directly. MS (ES + ): 170.4 (M+H) + . Intermediate 10: 1-methyl-1H-pyrazole-4-thiol Step 1 A mixture of 4-iodo-1-methyl-1H-pyrazole (1.00g, 1 Eq, 4.81 mmol), 2-ethylhexyl 3- mercaptopropanoate (1.05g, 1.10 mL, 1 Eq, 4.81 mmol), DIPEA (684mg, 921μL, 1.1 Eq, 5.29 mmol), Pd2dba3 (220mg, 0.05 Eq, 240μmol) and Xantphos (278 mg, 0.1 Eq, 481μmol) in DMF (25 mL) was stirred at 100°C under nitrogen for 1.5h, then allowed to cool to room temperature. Water and DCM were added, and the layers were separated. The organic layer was washed with water, brine, dried (MgSO4) and absorbed on silica. The crude product was purified by chromatography on silica gel (40 g cartridge, 0-50% EtOAc/isohexane) to afford 2-ethylhexyl 3- ((1-methyl-1Hpyrazol-4-yl)thio)propanoate (1.27g, 4.1 mmol, 85 %, 96% Purity) as a pale yellow oil. MS (ES + ): 299 (M+H) + Step 2 Sodium ethanolate (543mg, 625μL, 21% Wt, 2.5 Eq, 1.68 mmol) was added dropwise to a solution of 2-ethylhexyl 3-((1-methyl-1H-pyrazol-4-yl)thio)propanoate (200mg, 1 Eq, 670μmol) in THF (3.00mL) at 0 C under nitrogen and the mixture was allowed to warm to room temperature and stirred for 20 minutes.1N HCl (1 mL) and DCM were added, and the layers separated through a phase separator. The organic layer was washed with brine, dried (MgSO4) and concentrated under vacuum to afford the crude title product as a pale yellow oil. The product was used without further purification in the next step. Synthesis of Examples Example 1: 6-((1H-pyrazol-4-yl)sulfonyl)-2-((5-methoxypyridin-2-yl)meth yl)phthalazin- 1(2H)-one Step 1 A mixture of 6-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)thio)phthal azin-1(2H)-one (Intermediate 2, 75.0 mg, 1 Eq, 228μmol) and cesium carbonate (223 mg, 3 Eq, 685μmol) in DMF (1.50 mL) was stirred at 70°C for 30 minutes. 2-(chloromethyl)-5-methoxypyridine hydrochloride (48.8 mg, 1.1 Eq, 25μmol) was added and the mixture stirred at room temperature overnight. Water and DCM were added, and the layers separated through a phase separator. The organic layer was washed with brine, dried (MgSO4) and concentrated under vacuum to afford crude 2-((5-methoxypyridin-2-yl)methyl)-6-((1-(tetrahydro-2H-pyran -2-yl)-1H-pyrazol-4- yl)thio)phthalazin-1(2H)-one. The product was used without further purification in the next step. Quantitative yield was assumed. Step 2 A mixture of 2-((5-methoxypyridin-2-yl)methyl)-6-((1-(tetrahydro-2H-pyran -2-yl)-1H-pyrazol-4- yl)thio)phthalazin-1(2H)-one and Oxone(309 mg, 2.2 Eq, 502μmol) in DMF (1.50 mL) was stirred overnight. Sat. NaHCO 3 and DCM were added and the layers separated. The organic layer was washed with brine, dried (MgSO4) and concentrated under vacuum to afford a crude mixture of 2-((5-methoxypyridin-2-yl)methyl)-6-((1-(tetrahydro-2H-pyran -2-yl)-1H-pyrazol-4- yl)sulfonyl)phthalazin-1(2H)-one and 6-((1H-pyrazol-4-yl)sulfonyl)-2-((5-methoxypyridin-2- yl)methyl)phthalazin-1(2H)-one. The mixture was dissolved in MeOH (1.5 mL) and hydrogen chloride (4N in dioxane) (41.6 mg, 285μL, 4.00 molar, 5 Eq, 1.14 mmol) was added. The mixture was stirred for 1h, then concentrated under vacuum. Sat. NaHCO3, 2N NaOH and DCM were added, and the layers separated. The organic layer was washed with brine, then absorbed on silica. The crude product was purified by chromatography on silica gel (4 g cartridge, 0-50% 10%(MeOH (0.7M NH3):DCM)):DCM) to afford 6-((1H-pyrazol-4-yl)sulfonyl)-2-((5- methoxypyridin-2-yl)methyl)phthalazin-1(2H)-one (40.8 mg, 98% Purity) as a white solid.1H NMR (DMSO) δ:13.91 (s, 1H), 8.64 – 8.59 (m, 2H), 8.57 – 7.96 (s (br), 2H), 8.43 (d, J = 8.4 Hz, 1H), 8.31 (dd, J = 8.4, 1.9 Hz, 1H),8.16 (d, J = 2.9 Hz, 1H), 7.33 (dd, J = 8.6, 3.0 Hz, 1H), 7.24 (d, J = 8.6 Hz, 1H), 5.38 (s, 2H), 3.78 (s, 3H). MS (ES+): 398 (M+H)+. Example 2: 2-((1H-pyrazol-3-yl)methyl)-6-((1-(difluoromethyl)-1H-pyrazo l-4- yl)sulfonyl)phthalazin-1(2H)-one Step 1 Nitrogen was bubbled through a mixture of 6-mercapto-2-((1-(tetrahydro-2H-pyran-2-yl)-1H- pyrazol-3-yl)methyl)phthalazin-1(2H)-one (Intermediate 6, 150 mg, 91% Wt, 1 Eq, 399 μmol), 1- (difluoromethyl)-4-iodo-1H-pyrazole (126mg, 1.3 Eq, 518 μmol), 1,10-phenanthroline (32.3 mg, 0.45 Eq, 179 μmol) and potassium carbonate (93.7 mg, 1.7Eq, 678 μmol) in DMF (2.5 mL) for 5 minutes. copper(I) iodide (16.7 mg, 0.22 Eq, 87.7 μmol) was added and the mixture stirred under nitrogen at 100°C for 4h, then allowed to cool to room temperature. Water and EtOAc were added and the layers separated. The organic layer was washed with brine, then absorbed on silica. The crude product was purified by chromatography on silica gel (12 g cartridge, 0-100% EtOAc/isohexane) to afford 6-((1-(difluoromethyl)-1H-pyrazol-4-yl)thio)-2-((1-(tetrahyd ro- 2H- pyran-2-yl)-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one (165 mg, 0.36 mmol, 99% Purity) as a white solid. MS (ES+): 459 (M+H)+ Step 2 A mixture of 6-((1-(difluoromethyl)-1H-pyrazol-4-yl)thio)-2-((1-(tetrahyd ro-2H-pyran-2-yl)-1H- pyrazol-3-yl)methyl)phthalazin-1(2H)-one (165 mg, 99%Wt, 1 Eq, 356μmol) and Oxone (482 mg, 2.2 Eq, 784μmol) in DMF (1.5 mL) was stirred overnight. Sat. NaHCO3 and DCM were added, and the layers separated through a phase separator. The organic layer was washed with brine, dried (MgSO4) and concentrated under vacuum to afford crude mixture of 6-((1-methyl-1H- pyrazol-3-yl)sulfonyl)-2-((1-(tetrahydro-2H-pyran-2-yl)-1H-p yrazol-3 yl)methyl)phthalazin-1(2H)- one and 2-((1H-pyrazol-3-yl)methyl)-6-((1-(difluoromethyl)-1H-pyrazo l-4-yl)sulfonyl)phthalazin- 1(2H)-one. The mixture was dissolved in MeOH (1.5 mL) and hydrogen chloride (4N in dioxane) (64.9 mg, 445 μL, 4.00 molar, 5 Eq, 1.78 mmol) was added. The mixture was stirred for 1.5h, then concentrated under vacuum. Sat. NaHCO3, 2N NaOH and DCM were added, and the layers separated. The organic layer was washed with brine, then absorbed on silica. The crude product was purified by chromatography on silica gel (4 g cartridge, 0-50% 10% (MeOH (0.7M NH3):DCM)):DCM) to afford the title compound (48.5 mg, 99% Purity) as a white solid.1H NMR (DMSO) δ: 12.65 (s, 1H), 9.15 (s, 1H), 8.67 (d, J = 1.8 Hz, 1H), 8.61 (s, 1H), 8.47 (d, J = 8.5 Hz, 1H), 8.40 (s, 1H), 8.36 (dd, J = 8.5, 1.9 Hz, 1H), 7.85 (t, J = 58.3, 1H), 7.62 (s, 1H), 7.37 (s, 1H), 6.16 – 6.11 (m, 1H), 5.31 (s, 2H). MS (ES+): 407 (M+H)+ Example 3: 2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)methyl)-6-((1-(2-hydr oxyethyl)-1H- pyrazol-4-yl)sulfonyl)phthalazin-1(2H)-one
Step 1 A suspension of 6-mercaptophthalazin-1(2H)-one (Intermediate 7, 235 mg, 92% Wt, 1 Eq, 1.21 mmol), 1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-iodo-1H-pyrazole (Intermediate 8, 540 mg, 86% Wt, 1.09 Eq, 1.32 mmol), 1,10-phenanthroline (87.5 mg, 0.4 Eq, 485μmol) and potassium carbonate (335 mg, 2 Eq, 2.43 mmol) in DMF (6.00 mL) was sparged with N2 for 5-10 min before adding copper(I) iodide (46.2 mg, 0.2 Eq, 243μmol) and further sparging with N2 for 5-10 min. The reaction was stirred at 100 °C overnight then allowed to cool to rt. The reaction mixture was partitioned between DCM (20 mL) and water (10 mL). The organic was further washed with half concentrated brine (20 mL x2), filtered through a phase separator, and concentrated under reduced pressure to give a dark green crude oil (964 mg). The crude was dissolved in DCM ( 20 mL), concentrated onto silica and purified by chromatography on silica gel (24 g cartridge, 0-100% (3:1 EtOAc/EtOH)/isohexane) to afford 6-((1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-pyrazol-4- yl)thio)phthalazin-1(2H)-one (308.6 mg, 0.74 mmol, 97% Purity) as an off-white solid. MS (ES+): 403.1 (M+H)+.1H NMR (400 MHz, DMSO) δ 12.59 (s, 1H), 8.19 (d, J = 0.8 Hz, 1H), 8.13 (d, J = 0.7 Hz, 1H), 8.05 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 0.7 Hz, 1H), 7.53 (d, J = 1.9 Hz, 1H), 7.46 (dd, J = 8.5, 1.9 Hz, 1H), 4.28 (t, J = 5.1 Hz, 2H), 3.95 (t, J = 5.2 Hz, 2H), 0.78 (s, 9H), -0.06 (s, 6H). Step 2 A suspension of 6-((1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-pyrazol-4-y l)thio)phthalazin- 1(2H)-one (164 mg, 97% Wt, 1.00 Eq, 395μmol) and cesium carbonate (463 mg, 3.6 Eq, 1.42 mmol) in DMF (2.00mL) was stirred at 70 °C for 45 min before adding a solution of 5- (chloromethyl)-2,3-dihydrofuro[3,2-b]pyridine, HCl (Intermediate 9, 90.0 mg, 92% Wt, 1.02 Eq, 402μmol) in DMF (1.80mL). The reaction mixture was stirred at 50 °C for 5h then left to stand at rt overnight. The reaction mixture was heated at 50 °C for another 5h. The reaction mixture was precipitated with water (15 mL) and extracted with diluted in EtOAc (30mL x3). The combined organics was washed with a half-concentrated brine (50mL x 3), dried with Mg2SO4, filtered, concentrated under reduced pressure to give a yellow oil (204 mg). The crude was dissolved in DCM (10mL),concentrated onto silica and purified by chromatography on silica gel (12 g cartridge, 0-50% (3:1, EtOAc/EtOH)/isohexane) to afford 6-((1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H- pyrazol-4-yl)thio)-2-((2,3-dihydrofuro[3,2-b]pyridin-5-yl)me thyl)phthalazin-1(2H)-one (109.1 mg, 0.20 mmol, 97% Purity) as a yellow solid. MS (ES+): 536.1 (M+H)+.1H NMR (400 MHz, MeOD) δ 8.19 (s, 1H), 8.16 (d, J = 8.6 Hz, 1H), 7.96 (s, 1H), 7.71 (s, 1H), 7.54 (dd, J = 8.5, 1.9 Hz, 1H), 7.49 (d, J = 1.8 Hz, 1H), 7.03 (s, 2H), 5.39 (s, 2H), 4.64 (t, J = 8.9 Hz, 2H), 4.33 (t, J = 5.0 Hz, 2H), 4.02 (t, J = 5.0 Hz, 2H), 3.26 (t, J = 8.9 Hz, 2H), 0.82 (s, 9H), -0.02 (s, 6H). Step 3 To a solution of 6-((1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1H-pyrazol-4-y l)thio)-2-((2,3- dihydrofuro[3,2-b]pyridin-5-yl)methyl)phthalazin-1(2H)-one (109 mg, 97% Wt, 1 Eq, 197μmol) in MeOH (2.00 mL) was added Oxone (243 mg, 2.0 Eq, 395μmol). The reaction was stirred at rt on before adding Oxone (24.3 mg, 0.2 Eq, 39.5μmol) and stirring at rt for another 3 h. The reaction mixture was diluted with MeOH (15 mL) to give a white solid (359 mg). The crude was dissolved in DCM (20 mL) and MeOH (3 mL), concentrated onto silica and purified by chromatography on silica gel (12 g cartridge, 0-5% (0.7 M Ammonia/MeOH)/DCM) to afford 2-((2,3-dihydrofuro[3,2- b]pyridin-5-yl)methyl)-6-((1-(2-hydroxyethyl)-1H-pyrazol-4-y l)sulfonyl)phthalazin-1(2H)-one (41.4 mg, 89μmol, 98% Purity) as a white solid. MS (ES+): 454.2 (M+H)+.1H NMR (400 MHz, DMSO) δ 8.62 (d, J = 2.5 Hz, 2H), 8.53 (s, 1H), 8.44 (d, J = 8.5 Hz, 1H), 8.31 (dd, J = 8.4, 1.8 Hz, 1H), 8.05 (d, J = 0.7 Hz, 1H), 7.05 (d, J = 8.3 Hz, 1H), 6.98 (d, J = 8.3 Hz, 1H), 5.34 (s, 2H), 4.94 (s, 1H), 4.59 (t, J = 8.8 Hz, 2H), 4.18 (t, J = 5.3 Hz, 2H), 3.74 – 3.70 (m, 2H), 3.18 (t, J = 8.8 Hz, 2H). Example 4: 6-((1H-pyrazol-4-yl)sulfonyl)-2-((2,3-dihydropyrazolo[5,1-b] oxazol-6- yl)methyl)phthalazin-1(2H)-one
Step 1 A mixture of 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-thiol (Intermediate 3, 62 g, 337 mmol), 6-bromophthalazin-1(2H)-one (54 g, 241 mmol), CuI (6.4 g, 33.7 mmol) and 1,2,3-Benztriazole (8 g, 67.4 mmol) in NMP (2 L) was added t-BuOK (54 g, 482 mmol) at room temperature. The reaction was stirred at 100 °C overnight under nitrogen atmosphere. After LCMS indicated the reaction was completed, the reaction mixture was added to the water (10 L), stirred at room temperature for 3 hours and filtered. The residue was lyophilized to give 6-((1-(tetrahydro-2H- pyran-2-yl)-1H-pyrazol-4-yl)thio)phthalazin-1(2H)-one (75 g, 98% purity) as a yellow solid. MS (ES+): 329.1 (M+H)+. Step 2 To the solution of 6-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)thio)phthal azin-1(2H)-one (328 mg, 1 mmol) and 6-(chloromethyl)-2,3-dihydropyrazolo[5,1-b]oxazole (Intermediate 1, 200 mg, 1.3 mmol) in DMF (10 mL) was added Cs2CO3 (652 mg, 2 mmol) at room temperature, and the reaction mixture was stirred at 60 °C for 16 hours. After LCMS indicated the reaction was completed, to the reaction mixture was added water (30 mL) and the organics extracted with EtOAc (20 mL×3). The combined organic layer was washed by NH4Cl aq, dried over Na2SO4, filtered and concentrated at 45 °C under reduced pressure. The residue was purified by flash column chromatography (12 g, dichloromethane/ethyl acetate = 100:0~60:40) to give 2-((2,3- dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-((1-(tetrahydro- 2H-pyran-2-yl)-1H-pyrazol-4- yl)thio)phthalazin-1(2H)-one (170 mg, 89.77% purity) as a yellow solid. MS (ES+): 451.1 (M+H)+. Step 3 To the solution of 2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-((1-(tet rahydro-2H-pyran- 2-yl)-1H-pyrazol-4-yl)thio)phthalazin-1(2H)-one (170 mg, 0.38 mmol) in DMF (3 mL) was added OXONE (700 mg, 1.14 mmol) at room temperature. The reaction was stirred at 60 °C for 0.5 hours. After LCMS indicated the reaction was completed, to the reaction mixture was added water (10 ml). The mixture was extracted with EtOAc (10 mL × 3). The organic layers were concentrated at 40 °C under reduced pressure. The residue was purified by prep-HPLC (Column: Waters X- Bridge C18 OBD 10μm 19*250mm; Flow Rate: 20 mL/min; solvent system: MeCN/(10mmol/L NH4HCO3/water) gradient: MeCN: 38%~95%; collection wavelength: 214 nm). The relevant fractions were concentrated at 42 °C under reduced pressure to remove MeCN, and the residue was lyophilized to afford the title compound (27.87 mg, 100% purity) as a white solid. MS (ES+): 399.2 (M+H)+.1H NMR (400 MHz, DMSO-d6) δ: 13.91 (s, 1H), 8.60 (d, J = 1.6 Hz, 1H), 8.59 (d, J = 0.4 Hz, 1H), 8.44-8.29 (m, 4H), 5.31 (s, 1H), 5.16 (s, 2H), 4.99 (t, J = 8.0 Hz, 2H), 4.17 (t, J = 8.0 Hz, 2H).1H NMR (400 MHz, DMSO-d6+TFA-D) δ: 8.60 (d, J = 0.4 Hz, 1H), 8.59 (d, J = 2.0 Hz, 1H), 8.43 (d, J = 8.4 Hz, 1H), 8.34 (s, 2H), 8.30 (dd, J = 8.4, 2.0 Hz, 1H), 5.31 (s, 1H), 5.16 (s, 2H), 4.99 (t, J = 7.6 Hz, 2H), 4.17 (d, J = 8.4 Hz, 2H). Example 5: 2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-((1-meth yl-1H-pyrazol-4- yl)sulfonyl)phthalazin-1(2H)-one Step 1 A mixture of 1-methyl-1H-pyrazole-4-thiol (Intermediate 10, 27 g, 237 mmol), 6-bromophthalazin- 1(2H)-one (38g, 169 mmol), CuI (3.2 g, 16.9 mmol) and 1,2,3-Benztriazole (4 g, 33.8 mmol) in NMP (1 L) was added t-BuOK (38 g, 338 mmol) at room temperature. The reaction was stirred at 100 °C overnight under nitrogen atmosphere. After LCMS indicated the reaction was completed, the reaction mixture was added to the water (10 L), stirred at room temperature for 3 hours and then filtered. The residue was lyophilized to give 7-((1-methyl-1H-pyrazol-4-yl)thio)phthalazin- 1(2H)-one (32.5 g, 100% purity) as a yellow solid. MS (ES+): 259.1 (M+H)+. Step 2 To a solution of 7-((1-methyl-1H-pyrazol-4-yl)thio)phthalazin-1(2H)-one (258 mg, 1 mmol) and 6- (chloromethyl)-2,3-dihydropyrazolo[5,1-b]oxazole (Intermediate 1, 200 mg, 1.3 mmol) in DMF (10 mL) was added Cs2CO3 (652 mg, 2 mmol) at room temperature, and the reaction mixture was stirred at 60 °C for 16 hours. After LCMS indicated the reaction is completed, the reaction mixture was added water (30 mL) and extracted with EtOAc (20 mL×3). The combined organic layer was washed by NH 4 Cl aq, dried over Na 2 SO 4 , filtered and concentrated at 45 °C under reduced pressure. The residue was purified by flash column chromatography (12 g, dichloromethane/ethyl acetate = 100:0~60:40) to give 2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-((1-meth yl- 1H-pyrazol-4-yl)thio)phthalazin-1(2H)-one (140 mg, 89.77% purity) as a yellow solid. MS (ES+): 381.1 (M+H)+. Step 3 To a mixture of 2-((2,3-dihydropyrazolo[5,1-b]oxazol-6-yl)methyl)-6-((1-meth yl-1H-pyrazol-4- yl)thio)phthalazin-1(2H)-one (140 mg, 0.37 mmol) in DMF (3 mL) was added OXONE (700 mg, 1.14 mmol) at room temperature. The reaction was stirred at 60 °C for 0.5 hours. After LCMS indicated the reaction was completed, to the reaction mixture was added water (10 ml). The mixture was then extracted with EtOAc (10 mL × 3). The organic layers were concentrated at 40 °C under reduced pressure. The residue was purified by prep-HPLC (Column: Waters X-Bridge C18 OBD 10μm 19*250mm; Flow Rate: 20 mL/min; solvent system: MeCN/(10mmol/L NH4HCO3/water) gradient: MeCN: 38%~95%; collection wavelength: 214 nm). The relevant fractions were concentrated at 42 °C under reduced pressure to remove MeCN, and the residue was lyophilized afford the title compound (44.63 mg, 100% purity) as a white solid. MS (ES+): 413.2 (M+H)+.1H NMR (400 MHz, DMSO-d6) δ: 8.59 (s, 2H), 8.56 (s, 1H), 8.43 (d, J = 8.4 Hz, 1H), 8.29 (dd, J = 8.4, 2.0 Hz, 1H), 8.02 (d, J = 0.8 Hz, 1H), 5.31 (s, 1H), 5.16 (s, 2H), 4.99 (t, J = 7.8 Hz, 2H), 4.17 (t, J = 8.0 Hz, 2H), 3.87 (s, 3H). Example 6: 6-((1H-pyrazol-3-yl)sulfonyl)-2-((4-chloro-5-methyl-1H-pyraz ol-3- yl)methyl)phthalazin-1(2H)-one
Step 1 A mixture of 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-3-thiol (Intermediate 4, 2.8 g, 15.2 mmol), 6-bromophthalazin-1(2H)-one (2.9 g, 12.9 mmol), CuI (246 mg, 1.29 mmol) and 1,2,3- Benztriazole (307 mg, 2.58 mmol) in DMF (30 mL) was added t-BuOK (3.4 g, 30.4 mmol) at room temperature. The reaction was stirred at 100 °C overnight under nitrogen atmosphere. After LCMS indicated the reaction is completed, the reaction mixture was added to the water (200 mL), the solid was filtered and dried to give 6-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3- yl)thio)phthalazin-1(2H)-one (2.4 g, 72.75% purity) as a yellow solid. MS (ES+): 329.1 (M+H)+. Step 2 To a mixture of (4-chloro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3 -yl)methanol (Intermediate 5, 230 mg, 1.0 mmol) in DCM (4 mL) was added SOCl 2 (178 mg, 1.5 mmol). The reaction mixture was stirred at room temperature for 30 minutes. After LCMS analysis indicated the reaction was completed, the mixture was concentrated to remove the excess SOCl 2 and DCM to afford 4-chloro-3-(chloromethyl)-5-methyl-1-(tetrahydro-2H-pyran-2- yl)-1H-pyrazole as a crude product. This was used in the next step without further purification. Step 3 To the solution of the crude 4-chloro-3-(chloromethyl)-5-methyl-1-(tetrahydro-2H-pyran-2- yl)-1H- pyrazole in DMF (4 mL) was added Cs 2 CO 3 (1.95 g, 6.0 mmol) and 6-((1-(tetrahydro-2H-pyran-2- yl)-1H-pyrazol-3-yl)thio)phthalazin-1(2H)-one (328 mg, 1.0 mmol) at room temperature, and the reaction mixture was stirred at room temperature overnight. After LCMS indicated the reaction was completed, the reaction mixture was diluted with water (15 mL) and extracted with EtOAc (50 mL × 3). The combined organic layers were washed with saturated ammonium chloride solution (40 mL × 2), dried over Na2SO4, filtered, and concentrated at 40 °C under reduced pressure. The residual solid was purified by flash column chromatography (12 g, petroleum ether / ethyl actate = 100:00~60:30) to give 2-((4-chloro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazo l-3- yl)methyl)-6-((1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl) thio)phthalazin-1(2H)-one (200 mg, 100% purity) as a yellow solid. MS (ES+): 541.2 (M+H)+. Step 4 A solution of 2-((4-chloro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazo l-3-yl)methyl)-6-((1- (tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)thio)phthalazin-1 (2H)-one (200 mg, 0.37 mmol) in DMF (3 mL) was added OXONE (682 mg, 1.11 mmol) and stirred at 60 °C for 1 hour. After LCMS indicated the reaction was completed, the reaction mixture was diluted with water (5 mL), neutralized with K 2 CO 3 and extracted with EtOAc (10 mL × 4). The organic layers were The organic layers were washed with sat.aq.NH 4 Cl (100 mL×2), concentrated and purified by flash column chromatography (12 g, dichloromethane / methanol = 100:00~95:5) to give 2-((4-chloro- 5-methyl-1H-pyrazol-3-yl)methyl)-6-((1-(tetrahydro-2H-pyran- 2-yl)-1H-pyrazol-3- yl)sulfonyl)phthalazin-1(2H)-one (180 mg, 81% purity) as white solid. MS (ES+): 489.2 (M+H)+. Step 5 To a solution of 2-((4-chloro-5-methyl-1H-pyrazol-3-yl)methyl)-6-((1-(tetrahy dro-2H-pyran-2-yl)- 1H-pyrazol-3-yl)sulfonyl)phthalazin-1(2H)-one (180 mg, 0.37 mol) in DCM (1 mL) was added TFA (3 mL) and the mixture was stirred at room temperature for 1 hour. After LCMS indicated the reaction completed, the mixture was concentrated under reduced pressure. The residue was diluted with H 2 O (15 mL) and adjusted pH to 8 with K 2 CO 3 . Solid precipitated and the suspension was filtered. The filtered cake was purified by prep-HPLC (Column: Waters Xbridge Prep C18 OBD 10μm 19*250mm; Flow Rate: 20 mL/min; solvent system: MeCN/(10 mmol/L NH 4 HCO 3 /water) gradient: MeCN: 25%~95%; collection wavelength: 214 nm). The fractions were concentrated at 40 °C under reduced pressure to remove MeCN, and the residue was lyophilized to afford the title compound (24.64 mg, 100% purity) as white solid. MS (ES+): 405.2 (M+H)+. 1 H NMR (400 MHz, DMSO-d6) δ: 13.98 (br, 1H), 12.79 (br, 1H), 8.62 (s, 2H), 8.46 (d, J = 8.4 Hz, 1H), 8.29 (dd, J = 8.4 Hz, 1.6 Hz, 1H), 8.03 (d, J = 2.4 Hz, 1H), 6.96 (d, J = 2.4 Hz,1H), 5.28 (s, 2H), 2.14 (s, 3H). Biological Example 1 – human PKM2 activation assay Measuring in vitro activation of recombinant human PKM2 Compound activation of recombinant human PKM2 pyruvate kinase activity was determined by biochemical assay. N-terminal His-tagged hPKM2 was sourced from R&D Systems and its substrates phosphoenolpyruvate (PEP) and ADP from Sigma-Aldrich and 2Bscientific Ltd, respectively. The Kinase-Glo ® Plus luminescence assay was from Promega. All other reagents were from Sigma-Aldrich. Test Compounds were prepared as 10 mM DMSO stocks and dilution series prepared in DMSO for direct dilution into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2). Assay Procedure Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentration of 5 pM. Enzyme-Assay Buffer mix was dispensed into a 384-well shallow-well white-walled plate (PerkinElmer) and Test Compounds added by acoustic dispense (Echo ® , Labcyte Inc.). Following 10 minutes’ incubation at room temperature, the enzyme reaction was initiated by acoustic dispensing of ADP+PEP substrate to final concentrations of 254 µM ADP and 53 µM ADP. After 60 minutes’ incubation on an orbital shaker (300 rpm, 26 °C), enzyme activity was quantified by the luminescent detection of generated ATP. Kinase-Glo ® Plus reagent was added to each well and the plates incubated for a further 15 minutes on an orbital shaker in the dark (300 rpm, 26 °C) before luminescence measurement on a plate reader (PHERAstar ® FSX, BMG Labtech). Percentage activation was calculated by normalising fluorescence signals to plate LOW (DMSO vehicle) and HIGH (5 µM TEPP-46) controls. EC 50 and E max values were determined from 4- parameter logistic fits of compound concentration-response curves. The compounds of formula (Ia) were tested and the results are shown in Table 1 below. Table 1 – PKM2 EC 50 values (µM) and E max values (%) hPKM2 EC50 hPKM2 C * in caes aa rom repea expermens Examples 1 to 6 were tested in this assay and exhibited improved PKM2-modulatory activity compared with mitapivat, as demonstrated by their lower EC50 and/or higher Emax values for PKM2 activation. Biological Example 2 – human PKLR activation assay Measuring in vitro activation of recombinant human PKLR Compound activation of recombinant human PKLR pyruvate kinase activity was determined by biochemical assay. N-terminal His-tagged enzyme was sourced from R&D Systems and its substrates phosphoenolpyruvate (PEP) and ADP from Sigma-Aldrich and 2Bscientific Ltd, respectively. The Kinase-Glo ® Plus luminescence assay was from Promega. All other reagents were from Sigma-Aldrich. Test Compounds were prepared as 10 mM DMSO stocks and dilution series prepared in DMSO for direct dilution into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl 2 , 0.01% Tween20, 0.05% BSA (pH 7.2). Assay Procedure Human PKLR was diluted into Assay Buffer to a final concentration of 5 pM. Enzyme-Assay Buffer mix was dispensed into 384-well shallow-well white-walled plates and Test Compounds added by acoustic dispense (Echo ® , Labcyte Inc). Following 10 minutes’ incubation at room temperature, the enzyme reaction was initiated by acoustic dispensing of ADP+PEP substrate to final concentrations of 254 µM ADP and 53 µM ADP. After 60 minutes incubation on an orbital shaker (300 rpm, 26 C), enzyme activity was quantified by the luminescent detection of generated ATP. Kinase-Glo ® Plus reagent was added to each well and the plates incubated for a further 15 minutes on an orbital shaker in the dark (300 rpm, 26 °C) before luminescence measurement on a plate reader (PHERAstar ® FSX, BMG Labtech). Percentage activation was calculated by normalising fluorescence signals to plate LOW (DMSO vehicle) and HIGH (5 µM TEPP-46) controls. EC 50 and E max values were determined from 4- parameter logistic fits of compound concentration-response curves. A number of Example compounds of formula (Ia) were tested and the results are shown in Table 2 below. Table 2 – PKLR EC50 values (µM) and Emax values (%) * indicates data from repeat experiments Examples 1 to 5 were tested in this assay and exhibited improved PKLR-modulatory activity compared with mitapivat, as demonstrated by their lower EC50 and/or higher Emax values for PKLR activation. Biological Example 3 – CD4+ T cell Pyruvate Kinase assay Measuring pyruvate kinase (PK) activity in human CD4+ T cell lysates PKM2 activators increase the pyruvate kinase activity of both recombinant human PKM2 protein and PKM2 in human cell lysates (Kung et al., 2012). Compound activation of pyruvate kinase in human CD4+ T cell lysates was determined by biochemical assay. Primary CD4+ T cells were used rather than cancer cell lines to improve the disease relevance of the assay. The PK assay was sourced from Abcam. All other reagents were sourced from ThermoFisher. Test compounds were prepared as 10 mM DMSO stocks and dilution series prepared in DMSO for addition to intact CD4+ T cells cultured in RPMI media containing 10% FBS. Assay Procedure Human CD4+ T cells were incubated with compound for 20 minutes and then washed twice in 1xPBS before resuspension in Abcam PK lysis buffer to prepare cell lysates. 10 μl PK assay Reaction Mix was added per well, including OXIRED™ PROBE. The plates were read using a BMG Labtech Pherastar plate reader at OD570nm in kinetic mode for 48 minutes (25 cycles of 2 minutes) at 25°C, protecting from light. Data Analysis Plates were blank-subtracted and ΔAbsorbance calculated by subtracting the first plate read within the linear range from the plate read at the timepoint of interest. PK activity is expressed as ΔAbsorbance and plotted against log [Compound]. Examples 1 to 6 were tested and the results are shown in Table 3 below. Mitapivat was tested as a comparator compound. Table 3 – CD4+ T cell Pyruvate Kinase Activity Examples 1 to 6 were tested in this assay and exhibited improved pyruvate kinase activity, as demonstrated by its EC50 value, compared with mitapivat. References Abulizi et al. Cell Metab.2020, 32(5):751-766.e11. Alves-Filho et al. Front Immunol.2016, 7(145), 1-7. Barazzoni et al. Eating and Weight Disorders – Studies on Anorexia, Bulimia and Obesity 2018, 23, 149-157. Bettaieb et al. The Journal of Biological Chemistry 2013, 288(24), 17360-17371. Bianchi et al. Haematologica 2020, 105(9), 2218-2228. Cançado et al., Hematology, Transfusion and Cell Therapy, 2018, 40 (1), 1-2. Chhipa et al. Life Sciences 2018, 280, DOI: 10.1016/j.lfs.2021.119694. Dong et al. Oncol Lett.2016, 11(3), 1980–1986. Grace et al. N. Engl. J. Med.2019, 381(10), 933-944 Kung et al. Chemistry & Biology 2012, 19, 1187-1198 Kung et al. Blood 2017, 14;130(11), 1347-1356. Lewandowski et al. Cell Metab.2020, 32(5):736-750.e5. Liu et al. J. Diabetes Investig.2020, 12(5):697-709. Pålsson-McDermott et al. Cell Research 2020, 30:300–314. Puckett et al. International Journal of Molecular Sciences 2021, 22, 1171. Qi et al. Nat Med.2017, 23(6), 753-762 Yi et al. Front. Immunol.2021, DOI: 10.3389/fimmu.2020.595316. Miscellaneous All references referred to in this application, including patent and patent applications, are incorporated herein by reference to the fullest extent possible. Throughout the specification and the claims which follow, unless the context requires otherwise, the word ‘comprise’, and variations such as ‘comprises’ and ‘comprising’, will be understood to imply the inclusion of a stated integer, step, group of integers or group of steps but not to the exclusion of any other integer, step, group of integers or group of steps. The application, of which this description and claims form part, may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process, or use claims and may include, by way of example and without limitation, the following claims.